Galectin Therapeutic Inc. (NASDAQ: GALT) Rises Sharply in 6/23 Early Trading Session

June 23, 2026 10:15:56

Galectin Therapeutics Inc. (NASDAQ: GALT) is one of today’s top gainers. The company’s shares have moved 13.04% on the day to $3.17.

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company’s flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring.

So far today, approximately 456.29k shares of Galectin Therapeutics Inc. have been exchanged, as compared to an average 30-day volume of 320.04k shares.

Galectin Therapeutics Inc. share prices have moved between a 52-week high of $7.13 and a 52-week low of $2.03. The stock has moved 1.08% over the past week.

To learn more, visit Galectin Therapeutics Inc.

Receive IBN News Alerts – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN News Alerts, please visit https://IBN.fm/connected

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]